← Back to patent-cliff list
Cordycepin
Tier C — Watch / tradeCordycepin
Danisco
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：淋巴细胞减少症, Solid tumour, Lymphocytic leukaemia, Leukaemia
Regional status
US
No progress
1997-12-01
EU
-
China
Phase II
2025-12-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cordycepin?
Approved indications include: 淋巴细胞减少症, Solid tumour, Lymphocytic leukaemia, Leukaemia.
When does the Cordycepin patent expire?
No public expiry year is available for Cordycepin yet; this page updates once verified.
How do I get a quote for Cordycepin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29